Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.


Kudahetti, SC; Fisher, G; Ambroisine, L; Prowse, D; Kattan, MW; Foster, CS; Møller, H; Oliver, T; Fletcher, A; Cooper, C; Reuter, V; Scardino, P; Cuzick, J; Berney, DM; Transatlantic Prostate Group, ; (2010) Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology, 42 (6). pp. 519-23. ISSN 0031-3025 DOI: https://doi.org/10.3109/00313025.2010.508788

Full text not available from this repository.

Abstract

Treatment decisions are difficult in clinically localised prostate cancer and further biomarkers of aggressive behaviour are required. We investigated the hypothesis that the tissue expression of three cell cycle markers, Rb, p21 and p16, would provide helpful prognostic information in a well characterised series of prostate cancers which were clinically localised and treated conservatively.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
PubMed ID: 20854069
Web of Science ID: 282630000003
URI: http://researchonline.lshtm.ac.uk/id/eprint/1677

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
285Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item